Reading this on a mobile device? Try our optimized mobile version here: http://r.smartbrief.com/resp/eapzCfbwoceTBjnhYvpd

November 26, 2012
BIO has teamed up with FedEx to offer member companies discounts of up to 35% off select FedEx Express, FedEx Ground and FedEx Home Delivery services through the BIO Business Solutions cost-savings program. Learn more.

The news summaries appearing in BIO SmartBrief are based on original information from news organizations and are produced by SmartBrief, Inc., an independent e-mail newsletter publisher. The information is not compiled or summarized by BIO. Questions and comments should be directed to SmartBrief at bio@smartbrief.com.

  Today's Top Story 
 
  • FDA gives orphan-drug designation to OXiGENE's leukemia drug
    The FDA granted orphan-drug status to OXiGENE's OXi4503, an experimental drug for acute myelogenous leukemia. The drug has demonstrated strong tumor-fighting activity in preclinical and clinical trials, CEO Peter Langecker said. OXiGENE plans to apply for orphan drug designation in the European Union. An early-stage trial is being backed by the Leukemia & Lymphoma Society. Pharmaceutical Business Review Online (11/22) LinkedInFacebookTwitterEmail this Story
The New You Starts Here.
Designed for busy healthcare professionals, FIU's online Healthcare MBA is transformative. Graduates emerge ready for a leadership role in healthcare, with a clear vision of how to lead collaboratively and advance the business of healthcare. Classes begin Fall 2015. Start here.

  Health Care & Policy 
 
  • Actelion seeks European approval for PAH drug macitentan
    Actelion Pharmaceuticals submitted an application to the European Medicines Agency seeking approval to market Opsumit, or macitentan, to treat pulmonary arterial hypertension. The company is positioning macitentan to be the successor of its blockbuster PAH drug Tracleer, which will lose its patent protection in 2015. Reuters (11/22) LinkedInFacebookTwitterEmail this Story
  • Ablynx, Algeta collaborate on cancer drug R&D
    Belgian firm Ablynx and Norway-based Algeta entered into an agreement to discover and develop cancer drugs using their proprietary technologies. The collaboration will focus on a novel targeted thorium conjugate, a combination of Ablynx's nanobodies and Algeta's thorium-227 alpha-pharmaceutical payload. PharmaTimes (U.K.) (11/22) LinkedInFacebookTwitterEmail this Story
Don't lose access to your customer's facility. We can help.
Rep-Clear: Watermark's Solution for ensuring access to your customers. Rep-Clear includes our proprietary platform for tracking all items associated with a Rep and our professional support staff to provide individual service, ensuring all items are up to date and access to a facility is not lost. View common rep excuses.

  Company & Financial News 
 
  • PlantForm lands DARPA contract to develop nerve agent antidote
    The U.S. Defense Advanced Research Projects Agency awarded PlantForm a contract worth $1.77 million to improve an enzyme that enhances protection against sarin gas and other nerve agents. "The prime application of this enzyme is in people who will be going into an area where the gas has been or might be released," president and CEO Don Stewart said. PlantForm will collaborate with Kentucky BioProcessing, Aragen Bioscience and Defence Research and Development Canada on the project. The Guelph Mercury (Ontario) (11/19) LinkedInFacebookTwitterEmail this Story
Clinical Trial Data Transparency Forum: Expert insights
Hear industry and academic thought leaders - from Duke Clinical Research Institute, GlaxoSmithKline, Eli Lilly and more - share valuable insight on their clinical trial data transparency and sharing initiatives. This video covers a number of key perspectives and trends.

  Food & Agriculture 
  • Staple crop genomics studies share $25.5M grants
    The U.K. Biotechnology and Biological Sciences Research Council awarded grants totaling $25.5 million to 11 international research projects that aim to enhance staple crops using genomic technologies. The projects will seek to identify genes and markers that could be used to improve drought resistance, disease and pest tolerance, environmental adaptation, and yields by examining the genomes of beans, wheat, rice and other crops essential in Asia and sub-Saharan Africa. The grant program is funded by BBSRC, the U.K. Department for International Development, the Bill and Melinda Gates Foundation, and India's Ministry of Science. GenomeWeb Daily News (free registration) (11/21) LinkedInFacebookTwitterEmail this Story
  Hot Topics 

Top five news stories selected by BIO SmartBrief readers in the past week.

  • Results based on number of times each story was clicked by readers.
  Industrial & Environmental 
  • 38 U.S. senators express support for Pentagon's biofuels plan
    A group of 38 senators wrote a letter to the Senate leadership, seeking the elimination of provisions in the defense spending bill that would curtail the Department of Defense's ability to invest in renewable fuels. "Alternative fuels will not supplant fossil fuels entirely; however, replacing even a fraction of the fuels consumed by DOD with domestic alternative fuels has the potential to advance U.S. national security, improve strategic flexibility and insulate the defense budget against spikes in the cost of fossil fuels," the lawmakers wrote. Roll Call (free content) (11/25) LinkedInFacebookTwitterEmail this Story
The Buzz(CORPORATE ANNOUNCEMENTS)

Interested in learning more about advertising in BIO SmartBrief? Contact Meryl Harold at (202) 407-7828 or mharold@smartbrief.com. 

  News from BIO 
  • BIOtechNOW
    BIOtechNOW is the first in a number of new products from BIO intended to enhance our communications with the biotech community -- not only with our members, but with other stakeholders as well. This e-newsletter, combined with its website, serves as our flagship in that effort. BIOtechNOW will offer original content that emphasizes the business needs of the industry; highlight BIO's advocacy efforts; and provide a portal to all BIO activities and events. Most importantly, it will spotlight for those outside the industry the value of biotechnology. Sign up for the e-newsletter. LinkedInFacebookTwitterEmail this Story
Learn more about BIO ->Conferences  |  Join BIO  |  Media  |  Issues  |  Industry

  SmartQuote 
The passion for setting people right is in itself an afflictive disease."
--Marianne Moore,
American poet and writer


LinkedInFacebookTwitterEmail this Story

 
 
Subscriber Tools
     
Print friendly format | Web version | Search past news | Archive | Privacy policy

Advertise
Account Director:  Meryl Harold (202) 407-7828
 
Read more at SmartBrief.com
A powerful website for SmartBrief readers including:
 
 
 Recent BIO SmartBrief Issues:   Lead Editor:  Tom Parks
     
Mailing Address:
SmartBrief, Inc.®, 555 11th ST NW, Suite 600, Washington, DC 20004
 
 
© 1999-2012 SmartBrief, Inc.® Legal Information